Skip to main content

Table 1 Patient demographics of 86 patients underwent CRS+HIPEC

From: High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy

Characteristics Total (n=86)
Age at operation (y, mean ± SD) (range) 55.6 ± 11.7 (27–74)
Gender (%)
 Male 45 (52.3)
 Female 41 (47.7)
Preoperative chemotherapy (%) 41 (51.2)
Presentation of PM (%)
 Synchronous 52 (60.5)
 Metachronous 34 (39.5)
Site of original (%)
 Colon 63 (73.3)
 Rectum 23 (26.7)
Preoperative CEA level (ng, mean ± SD) (range) 33.4 ± 65.2 (0.6–291.7)
Preoperative CA19–9 level (ng, mean ± SD) (range) 68.3 ± 87.7 (0.7–363.5)
Histology (%)
 Adenocarcinoma 55 (64.0)
 Mucinous 31 (36.0)
Liver metastases 17 (19.8)
HIPEC regimen 5 (6.6)
 Lobaplatin+Oxaliplatin+Raltitrexed 40 (46.5)
 Oxaliplatin+Raltitrexed 46 (53.5)
PCI score 11.2 ± 5.7 (2–24)
Operation time (min, mean ± SD) (range) 264.0 ± 70.3 (145–510)
Estimated blood loss (ml, mean ± SD) (range) 121.4 ± 107.8 (20–500)
Presence of ascites 37 (43.0)
CC score
 CC 0–1 54 (62.8)
 CC 2–3 32 (37.2)
Postoperative Complications (grade 1–4) (%) 41 (47.7)
Postoperative Complications (grade 3–4) (%) 22 (25.6)
Mortality (%) 0 (0)
Total hospital stay (day, mean ± SD) (range) 15.4 ± 6.0 (7–44)